What is Elminda?
Elminda, operating within the advanced brain health analytics sector, leverages its FDA-cleared technology, Brain Network Analytics (BNA). This AI-driven platform provides objective measurements of brain activity, assisting healthcare professionals in the diagnosis and management of cognitive disorders. By targeting healthcare providers, patients, and investors, Elminda aims to enhance patient outcomes and streamline operational efficiency in neurological care. Its proprietary database and advanced AI position it as a leader in neurophysiological assessment and biomarker development.
How much funding has Elminda raised?
Elminda has raised a total of $28M across 1 funding round:
Series C
$28M
Series C (2015): $28M with participation from Palisade Capital Management, Shanda Group, Healthcrest AG, OurCrowd, WR Hambrecht, and Wexford Capital
Key Investors in Elminda
Palisade Capital Management
Palisade Capital Management is a financial services firm based in Pacific Palisades, California, likely focusing on strategic investments within its portfolio companies.
Shanda Group
Shanda Group, operating in the software industry, is a significant backer that may bring technological expertise and market access to Elminda's growth.
Healthcrest AG
Healthcrest AG, with deep industry knowledge in healthcare, likely provides strategic guidance and potential funding as a private equity partner, leveraging its entrepreneurial background.
What's next for Elminda?
With a substantial enterprise-level funding context, Elminda is poised for significant expansion and technological advancement. The recent strategic investment suggests a focus on scaling its BNA platform, potentially broadening its market reach and deepening its research capabilities. Future developments may include further integration of AI for predictive diagnostics and the establishment of new strategic partnerships within the healthcare ecosystem to accelerate the adoption of its innovative brain health analytics.
See full Elminda company page
